Antengene Corporation Limited (SEHK: 6996.HK), a China-based, commercial-stage global biopharmaceutical company, announced on Wednesday that it has named Amily Zhang as its new chief medical officer.

Dr Zhang is to replace Dr Kevin Lynch who will continue working with Antengene in a senior advisory role.

Dr Zhang has served in various key leadership positions in clinical development at Jiangsu Hengrui Pharmaceuticals, including vice president, head of Clinical Development - Oncology, corporate vice president and chief medical officer for Oncology. She has more than 20 years of experience in the field of oncology and pharmaceutical industry, including seven years of clinical practice as a medical oncologist and medical haematologist, around 18 years in oncology clinical development and medical affairs in the pharmaceutical industry and more than 10 years in leadership positions. She has served at Novartis China and Bayer in both the United States and China for over 12 years.